GMCL2

Across TCGA pan-cancer cohorts, GMCL2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GMCL2 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher GMCL2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GMCL2 expression acts as an unfavorable survival marker.

SKCM, LIHC, and UCEC are the cancer types where GMCL2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	III,IV	0.250	0.806	<.001	29	view →
LIHC	OS	Median	All	0.098	0.774	.001	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	OS	Median	All	0.528	0.870	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GMCL2–SKCM (OS)

Open the SKCM breakdown →